  | Shaker, B. T., Ismail, A. A., Salih, R., Hadj Kacem, H., Rahmani, M., Struman, I., & Bajou, K. (17 May 2023). The 14-Kilodalton Human Growth Hormone Fragment a Potent Inhibitor of Angiogenesis and Tumor Metastasis. International Journal of Molecular Sciences, 24 (10), 8877. doi:10.3390/ijms24108877  Peer Reviewed verified by ORBi |
 | Guiot, J., Henket, M., Remacle, C., Cambier, M., Struman, I., Winandy, M.-L., Moermans, C., Louis, E., Malaise, M., Ribbens, C., Louis, R., & Njock, M.-S. (15 April 2023). Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis. Respiratory Research, 24 (1), 112. doi:10.1186/s12931-023-02413-6 Peer Reviewed verified by ORBi |
Cambier, M., Muller, F., Henket, M., Remacle, C., Guiot, J., & Struman, I. (04 September 2022). Extracellular vesicles (EVs) as diagnostic tools in the phenotypic determination of lung tumors [Paper presentation]. ERS International Congress 2022, Barcelone, Spain. doi:10.1183/13993003.congress-2022.1370 |
 | NJOCK, M.-S.* , O'Grady, T.* , Nivelles, O., Lion, M., Jacques, S., Cambier, M., Herkenne, S., Muller, F., Christian, A., REMACLE, C., GUIOT, J., Rahmouni, S., Dequiedt, F.* , & Struman, I.*. (June 2022). Endothelial extracellular vesicles promote tumour growth by tumour-associated macrophage reprogramming. Journal of Extracellular Vesicles, 11 (6), 12228. doi:10.1002/jev2.12228 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | O'Grady, T.* , NJOCK, M.-S.* , Lion, M., Bruyr, J., Mariavelle, E., Galvan, B., Boeckx, A., Struman, I.* , & Dequiedt, F.*. (24 March 2022). Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels. BMC Biology, 20 (1), 72. doi:10.1186/s12915-022-01277-4 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Zamberlan, M.* , Boeckx, A.* , Muller, F., Vinelli, F., Ek, O., Vianello, C., Coart, E., Shibata, K., Christian, A., Grespi, F., Giacomello, M., Struman, I., Scorrano, L.* , & Herkenne, S.*. (12 March 2022). Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. Journal of Experimental and Clinical Cancer Research, 41 (1), 95. doi:10.1186/s13046-022-02304-6 Peer reviewed* These authors have contributed equally to this work. |
 | Fontaine, M., Herkenne, S., Ek, O., Paquot, A., Boeckx, A., Paques, C., Nivelles, O., Thiry, M., & Struman, I. (2022). Extracellular Vesicles Mediate Communication between Endothelial and Vascular Smooth Muscle Cells. International Journal of Molecular Sciences, 23 (1). doi:10.3390/ijms23010331 Peer Reviewed verified by ORBi |
 | Bhardwaj, A., Josse, C., VAN DAELE, D., Poulet, C., Chavez, M., Struman, I., & Van Steen, K. (2022). Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual-and group-level transcriptome network analyses. Scientific Reports, 12 (11027). doi:10.1038/s41598-022-14592-1 Peer Reviewed verified by ORBi |
 | Cambier, M., Henket, M., Frix, A.-N., Gofflot, S., THYS, M., Tomasetti, S., Peired, A., Struman, I., Rousseau, A.-F., Misset, B., Darcis, G., Moutschen, M., Louis, R., Njock, M.-S., Cavalier, E., & Guiot, J. (2022). Increased KL-6 levels in moderate to severe COVID-19 infection. PLoS ONE, 17 (11), 0273107. doi:10.1371/journal.pone.0273107 Peer Reviewed verified by ORBi |
 | Roblain, Q., Louis, T., Yip, C., Baudin, L., Struman, I., Caolo, V., LAMBERT, V., Lecomte, J.* , Noël, A.* , & Heymans, S.*. (2021). Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging, 13. doi:10.18632/aging.203035 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
  | Guiot, J., HENKET, M., NJOCK, M.-S., MOERMANS, C., Struman, I., Corhay, J.-L., & Louis, R. (2021). La fibrose pulmonaire : des biomarqueurs à de nouveaux horizons thérapeutiques. Revue Médicale de Liège, 76 (3), 166-172. Peer reviewed |
 | Parzibut, G., Henket, M., Moermans, C., Struman, I., Louis, E., Malaise, M., Louis, R., Misset, B., NJOCK, M.-S.* , & Guiot, J.*. (2021). A Blood Exosomal miRNA Signature in Acute Respiratory Distress Syndrome. Frontiers in Molecular Biosciences, 8, 640042. doi:10.3389/fmolb.2021.640042 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | GUIOT, J., Cambier, M., Boeckx, A., HENKET, M., Nivelles, O., GESTER, F., LOUIS, E., MALAISE, M., Dequiedt, F., LOUIS, R., Struman, I.* , & NJOCK, M.-S.*. (05 August 2020). Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax, 75 (10), 870-881. doi:10.1136/thoraxjnl-2019-214077 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Pérez-Boza, J., Boeckx, A., Lion, M., Dequiedt, F., & Struman, I. (2020). hnRNPA2B1 inhibits the exosomal export of miR‑503 in endothelial cells. Cellular and Molecular Life Sciences. doi:10.1007/s00018-019-03425-6 Peer Reviewed verified by ORBi |
 | Francart, M.-E.* , Vanwynsberghe, A.* , Lambert, J., Bourcy, M., Genna, A., Ancel, J., Perez-Boza, J., Noël, A., Birembaut, P., Struman, I., Polette, M., & Gilles, C. (2020). Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis. Oncogene, 18, 3680-3692. doi:10.1038/s41388-020-1244-1 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Boeckx, A., Gourzonès, C., & Struman, I. (06 September 2019). The exosomal microRNA miR-503: a key modulator of resistance to chemotherapy in breast cancer cells [Poster presentation]. EDT-CANCEROLOGY ANNUAL MEETING 2019 RECENT BREAKTHROUGHS IN ANTICANCER DRUG RESISTANCE. |
 | BONHOMME, O., ANDRE, B., GESTER, F., DE SENY, D., MOERMANS, C., Struman, I., Louis, R., MALAISE, M., & GUIOT, J. (2019). Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology (Oxford, England). doi:10.1093/rheumatology/kez230 Peer reviewed |
 | GUIOT, J., Struman, I., Louis, E., Louis, R., Malaise, M., & Njock, M.-S. (2019). Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets. Journal of Clinical Medicine, 8 (9). doi:10.3390/jcm8091345 Peer Reviewed verified by ORBi |
 | Boeckx, A., Pérez-boza, J., & Struman, I. (14 September 2018). Underlying the exosomal export of a specific microRNA, miR-503, and its implication in resistance to chemotherapy [Poster presentation]. BESEV (Belgian Society for Extracellular Vesicles) First Annual meeting, Gand, Belgium. |
Dederen, S., Gourzonès, C., & Struman, I. (13 September 2018). Cell communication via microRNA exchange between endothelial and tumour cells during anti-cancer neoadjuvant therapy [Poster presentation]. JOINT MEETING GIGA-CANCER DAY 2018/EDT-CANCEROLOGY. |
Njock, M.-S., O'Grady, T., Nivelles, O., Dequiedt, F., & Struman, I. (13 September 2018). Tumor microenvironment affects the composition of endothelial-derived exosomes: impact in tumor progression [Paper presentation]. GIGA-CANCER DAY, Liège, Belgium. |
 | Boeckx, A., Pérez-Boza, J., & Struman, I. (13 September 2018). Underlying the exosomal export of the microRNA, miR-503, and its implication in the resistance to chemotherapy [Poster presentation]. Joint meeting GIGA-Cancer Day 2018/ EDT-Cancerology, Liège, Belgium. |
Pollenus, T., & Struman, I. (June 2018). Study of the crosstalk between VEGF and BMP9 pathways: implications in HHT [Poster presentation]. International Vascular Biology Meeting 2018 (IVBM2018), Helsinki, Finland. |
Dederen, S., & Struman, I. (03 May 2018). Cell communication via microRNA exchange between endothelial and tumour cells during anti-cancer neoadjuvant therapy [Poster presentation]. ISEV2018. |
Njock, M.-S., GUIOT, J., HENKET, M., Nivelles, O., LOUIS, R., & Struman, I. (May 2018). Sputum exosomes - promising biomarkers for idiopathic pulmonary fibrosis [Poster presentation]. International Society for Extracellular Vesicles, Barcelone, Spain. doi:10.1080/20013078.2018.1461450 |
O'Grady, T., Njock, M.-S., Lion, M., Struman, I., & Dequiedt, F. (May 2018). Integrating long and short sequencing data for a global overview of the endothelial extracellular vesicle RNA landscape [Poster presentation]. International Society for Extracellular Vesicles, Barcelone, Spain. |
 | Pérez Boza, J., Lion, M., & Struman, I. (2018). Exploring the RNA landscape of endothelial exosomes. RNA. doi:10.1261/rna.064352.117 Peer Reviewed verified by ORBi |
 | Durré, T., Morfoisse, F., ERPICUM, C., Ebroin, M., Blacher, S., García Caballero, M., Deroanne, C., Louis, T., BALSAT, C., Van De Velde, M., Kaijalainen, S., Kridelka, F., Engelholm, L., Struman, I., Alitalo, K., Behrendt, N., Paupert, J., & Noël, A. (2018). uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis. Nature Communications, 9 (1), 5178. doi:10.1038/s41467-018-07514-1 Peer Reviewed verified by ORBi |
 | Njock, M.-S., GUIOT, J., HENKET, M., Nivelles, O., Thiry, M., Dequiedt, F., Corhay, J.-L., Louis, R., & Struman, I. (2018). Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax. doi:10.1136/thoraxjnl-2018-211897 Peer Reviewed verified by ORBi |
 | GUIOT, J., Struman, I., CHAVEZ, V., HENKET, M., Herzog, M., Scoubeau, K., Hardat, N., Bondue, B., Corhay, J.-L., MOERMANS, C., & Louis, R. (15 August 2017). Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis. Clinical Epigenetics, 9, 84. doi:10.1186/s13148-017-0383-x Peer Reviewed verified by ORBi |
 | Njock, M.-S., O'Grady, T., Dequiedt, F., & Struman, I. (2017). Tumour microenvironment affects the composition of endothelial cell-derived extracellular vesicles: impact in tumour progression. Journal of Extracellular Vesicles. doi:10.1080/20013078.2017.1310414 |
Njock, M.-S., O'Grady, T., Nivelles, O., Dequiedt, F., & Struman, I. (2017). Tumor microenvironment affects the composition of endothelial-derived extracellular vesicles: Impact in tumor progression [Poster presentation]. International Society for Extracellular Vesicles Annual Meeting. |
 | Blomme, A., Fahmy, K., Peulen, O., Costanza, B., Fontaine, M., Struman, I., Baiwir, D., De Pauw, E., Thiry, M., Bellahcene, A., Castronovo, V.* , & Turtoi, A.*. (2016). Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes. Oncotarget. doi:10.18632/oncotarget.13276 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Pollenus, T., Paques, C., & Struman, I. (25 January 2016). Study of the crosstalk between the VEGF and the BMP9 pathways and their implication in Hereditary Hemorrhagic Telengiectasia [Poster presentation]. GIGA-DAY 2016. |
Fontaine, M., Paquot, A., Paques, C., & Struman, I. (25 January 2016). Implication of miR-539 and miR-582 in the angiogenesis and the communication between endothelial cells and vascular smooth muscle cells [Poster presentation]. GIGA Day 2016. |
 | Rambout, X., Detiffe, C., Bruyr, J., Mariavelle, E., Cherkaoui, M., Brohee, S., Demoitie, P., Lebrun, M., Soin, R., Lesage, B., Guedri, K., Beullens, M., Bollen, M., Farazi, T. A., Kettmann, R., Struman, I., Hill, D. E., Vidal, M., Kruys, V., ... Dequiedt, F. (2016). The transcription factor ERG recruits CCR4-NOT to control mRNA decay and mitotic progression. Nature Structural and Molecular Biology. doi:10.1038/nsmb.3243 Peer Reviewed verified by ORBi |
 | Freres, P.* , Wenric, S.* , BOUKERROUCHA, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., COLLIGNON, J., SCHROEDER, H., KRIDELKA, F., LIFRANGE, E., Jossa, V., Bours, V.* , Josse, C.* , & JERUSALEM, G.*. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. doi:10.18632/oncotarget.6786 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Fontaine, M., Paques, C., & Struman, I. (24 September 2015). Implication of miRNAs in the communication between endothelial cells and vascular muscle cells [Poster presentation]. 6ème congrès de la Société Française d'Angiogenèse. |
Fontaine, M., Paques, C., & Struman, I. (11 September 2015). Implication of miRNAs in the communication between endothelial cells and vascular muscle cells [Poster presentation]. EDT-Cancérologie. |
Fontaine, M., Bovy, N., & Struman, I. (13 May 2015). Implication of miRNAs in the communication between endothelial cells and vascular muscle cells [Poster presentation]. GIGA-Cancer Day 2015. |
Pollenus, T., Paques, C., & Struman, I. (May 2015). Study of the crosstalk between the VEGF and the BMP9 pathways and their implication in Hereditary Hemorrhagic Telengiectasia [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Fontaine, M., Bovy, N., & Struman, I. (27 January 2015). Study of the communication between endothelial cells and vascular smooth muscle cells via microRNAs and its implication on angiogenesis [Poster presentation]. GIGA Day 2015. |
 | Herkenne, S., Paques, C., Nivelles, O., Lion, M., BAJOU, K., Pollenus, T., Fontaine, M., Carmeliet, P., Martial, J., Nguyen, N.-Q.-N., & Struman, I. (2015). The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis. Science Signaling, 8 (403), 117. doi:10.1126/scisignal.aaa2403 Peer Reviewed verified by ORBi |
 | Shiva Shankar, T. V., Sulka, B., Hubert, P., Hubaux, R., Delvenne, P., Pendeville-Samain, H., Boittiaux, I., Lambert, D. M., Wouters, J., Maillard, C., Blacher, S., Noël, A., Struman, I., & Willems, L. (2015). N-Hydroxy-6-(5-Nitro- Naphtalimide)-Hexanamide Inhibits Lysine Deacetylation, Mitigates Angiogenesis and Reduces Tumor Growth. Journal of Cancer Sciences, 2 (2), 0-11. Peer reviewed |
 | Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J., Noël, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S., & Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. doi:10.18632/oncotarget.3520 Peer Reviewed verified by ORBi |
Pollenus, T., Paques, C., & Struman, I. (January 2015). Crosstalk between the VEGF and the TGF-beta pathway and their implication in HHT [Poster presentation]. GIGA-DAY 2015, Liège, Belgium. |
 | FRERES, P., JOSSE, C., Bovy, N., Boukerroucha, M., Struman, I., BOURS, V., & JERUSALEM, G. (2014). Neoadjuvant chemotherapy in breast cancer induces miR-34a and miR-122 expression. Journal of Cellular Physiology. doi:10.1002/jcp.24730 Peer Reviewed verified by ORBi |
Fontaine, M., Bovy, N. (Other coll.), & Struman, I. (Other coll.). (19 May 2014). Study of the communication between endothelial cells and vascular smooth muscle cells via microRNAs and its implication on angiogenesis [Poster presentation]. GIGA-Cancer Day 2014, Liege, Belgium. |
Paques, C., Herkenne, S., Pollenus, T., & Struman, I. (May 2014). Growth Factors-Induced Angiogenesis Requires uPAR on Endothelial Cells [Poster presentation]. Giga Cancer Day, Liège, Belgium. |
Fontaine, M., Bovy, N. (Other coll.), & Struman, I. (Other coll.). (01 February 2014). Study of the communication between endothelial cells and vascular smooth muscle cells via microRNAs and its implication on angiogenesis [Poster presentation]. Keystone Symposia - RNA Silencing, Seattle, United States. |
Fontaine, M., Bovy, N. (Other coll.), & Struman, I. (Other coll.). (27 January 2014). Study of the communication between endothelial cells and vascular smooth muscle cells via microRNAs and its implication on angiogenesis [Poster presentation]. GIGA Day 2014, Liege, Belgium. |
 | Valencia, K., Luis-Ravelo, D., Bovy, N., Anton, I., Martinez-Canarias, S., Zandueta, C., Ormazabal, C., Struman, I., Tabruyn, S., Rebmann, V., De Las Rivas, J., Guruceaga, E., Bandres, E., & Lecanda, F. (2014). miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Molecular Oncology, 8 (3), 689-703. doi:10.1016/j.molonc.2014.01.012 Peer Reviewed verified by ORBi |
 | Bajou, K.* , Herkenne, S.* , Thijssen, V. L., D'Amico, S., Nguyen, N.-Q.-N., Bouche, A., Tabruyn, S., Srahna, M., Carabin, J.-Y., Nivelles, O., Paques, C., Cornelissen, Y., Lion, M., Noël, A., Gils, A., Vinckier, S., Declerck, P. J., Griffioen, A. W., Dewerchin, M., ... Struman, I. (2014). PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature Medicine, (7), 741. doi:10.1038/nm.3552 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Fontaine, M., Halkein, J. (Other coll.), Tabruyn, S. (Other coll.), & Struman, I. (Other coll.). (17 May 2013). Endothelium-specific expression of the microRNA miR-146a by using the RCAS system [Poster presentation]. GIGA-Cancer Day 2013, Liège, Belgium. |
 | Erpicum, C., Detry, B., Paupert, J., Maertens, L., Blacher, S., Maillard, C., Thiry, M., Orménèse, S., Struman, I., Behrendt, N., & Noël, A. (28 January 2013). Lymphangiogenesis and extracellular matrix remodeling [Paper presentation]. GIGA-Day, Liège, Belgium. |
Paques, C., Herkenne, S., & Struman, I. (2013). Tumor-Induced Angiogenesis Requires uPAR on Endothelial Cells [Poster presentation]. Giga Cancer Day. |
 | Haghikia, A., Podewski, E., Libhaber, E., Labidi, S., Fischer, D., Roentgen, P., Tsikas, D., Jordan, J., Lichtinghagen, R., von Kaisenberg, C. S., Struman, I., Bovy, N., Sliwa, K., Bauersachs, J., & Hilfiker-Kleiner, D. (2013). Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Research in Cardiology, 108 (4), 366. doi:10.1007/s00395-013-0366-9 Peer Reviewed verified by ORBi |
 | LAMBERT, V., Lecomte, J., Hansen, S., Blacher, S., Alvarez Gonzalez, M.-L., Struman, I., Sounni, N. E., Rozet, E., De Tullio, P., Foidart, J.-M., Rakic, J.-M., & Noël, A. (2013). Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nature Protocols, 8 (11), 2197-2211. doi:10.1038/nprot.2013.135 Peer Reviewed verified by ORBi |
 | Tabruyn, S. P., Hansen, S., Ojeda-Fernandez, M.-L., Bovy, N., Zarrabeitia, R., Recio-Poveda, L., Bernabeu, C., Martial, J., Botella, L.-M., & Struman, I. (2013). MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. Angiogenesis. doi:10.1007/s10456-013-9362-9 Peer Reviewed verified by ORBi |
 | Halkein, J., Tabruyn, S. P., Ricke-Hoch, M., Haghikia, A., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Thiry, M., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (2013). MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. Journal of Clinical Investigation, 123 (5), 2143-54. doi:10.1172/JCI64365 Peer Reviewed verified by ORBi |
 | Detry, B.* , Erpicum, C.* , Paupert, J.* , Blacher, S., Maillard, C., Bruyère, F., Pendeville, H., Remacle, T., LAMBERT, V., Balsat, C., Ormenese, S., Lamaye, F., Janssens, E., Moons, L., CATALDO, D., Kridelka, F., Carmeliet, P., Thiry, M., Foidart, J.-M., ... Noël, A. (24 May 2012). Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood, 119 (21), 5048-56. doi:10.1182/blood-2011-12-400267 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Herkenne, S., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (19 May 2012). Implication of the PAI-1/uPA/uPAR signalosome in the antiangiogenic action of 16K prolactin [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Bovy, N., Halkein, J., Martial, J., Tabruyn, S., & Struman, I. (19 May 2012). Circulating microRNAs as a new way of communication between endothelial and tumor cells [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (19 May 2012). MicroRNA-146a, a downstream effector of 16K prolactin, is a therapeutic target and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (April 2012). MicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. Biomedica, Liège, Belgium. |
Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (April 2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K prolactin [Poster presentation]. Biomedica, Liège, Belgium. |
Bovy, N., Halkein, J., Martial, J., Tabruyn, S., & Struman, I. (April 2012). Circulating microRNAs as a new way of communication between endothelial and tumor cells [Poster presentation]. Biomedica, Liège, Belgium. |
 | Soares, A. R., Reverendo, M., Pereira, P. M., Nivelles, O., Pendeville, H., Bezerra, A. R., Moura, G. R., Struman, I., & Santos, M. A. S. (2012). Dre-miR-2188 Targets Nrp2a and Mediates Proper Intersegmental Vessel Development in Zebrafish Embryos. PLoS ONE, 7 (6), 39417. doi:10.1371/journal.pone.0039417 Peer Reviewed verified by ORBi |
 | Hilfiker-Kleiner, D., Struman, I., Hoch, M., Podewski, E., & Sliwa, K. (2012). 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Current Heart Failure Reports, 9 (3), 174-82. doi:10.1007/s11897-012-0095-7 Peer Reviewed verified by ORBi |
| Struman, I., Halkein, J., Tabruyn, S., Haghiskia, A., Hoch, M., Nguyen, N.-Q.-N., Malvaux, L., sliwa, K., Noël, A., Martial, J., & Hilfiker-kleiner, D. (2012). MicroRNA-146a, a downstream effector of 16kDa prolactin, impairs the endothelium-cardiomyocyte cross-talk in peripartum cardiomyopathy. In FASEB meeting:the Growth Hormone/Prolactin Family in Biology and Disease. Peer reviewed |
Halkein, J., Tabruyn, S., Haghikia, A., Castermans, K., Malvaux, L., Lambert, V., Labidi, S., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (January 2012). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Keystone symposia on Angiogenesis advances in basic sciences and therapeutic applications, Snowbird Resort, Snowbird, Utah, United States. |
Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K hPRL [Poster presentation]. Keystone symposia on Angiogenesis: Advances in Basic Science and Therapeutic Applications, Snowbird, United States - Utah. |
 | D'Amico, S., Martial, J., & Struman, I. (2012). A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of Plasminogen Activator Inhibitor Type-1. FEBS Letters, 586, 686-692. doi:10.1016/j.febslet.2012.02.013 Peer Reviewed verified by ORBi |
 | Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318 Peer Reviewed verified by ORBi |
Struman, I., Martial, J., Bajou, K., & D'Amico, S. (25 August 2011). A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) – placental lactogen (PL)-family protein. |
Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (May 2011). The antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation [Poster presentation]. 4th International Meeting on Angiogenesis, Amsterdam, Netherlands. |
Paupert, J., Pendeville, H., Detry, B., Erpicum, C., Maillard, C., Struman, I., Foidart, J.-M., & Noël, A. (May 2011). Involvement of z-MMP-2 in Zebrafish lymphangiogenesis [Poster presentation]. Giga Cancer Day, Liège, Belgium. |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (March 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. IVth International Meeting on Angiogenesis, Amsterdam, Netherlands. |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (March 2011). Mir-146a : A new angiostatic miRNA with tumor-suppressive properties [Poster presentation]. IVth International Meeting on Angiogenesis, Amsterdam, Netherlands. |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (February 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Keystone Symposia : MicroRNAs and Human Disease, Banff, Alberta, Canada. |
Halkein, J., Bovy, N., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (February 2011). MiR-146a: an angiostatic miRNA with tumor-suppressive properties [Poster presentation]. Keystone Symposia : MicroRNAs and Non-Coding RNAs and Cancer, Banff, Alberta, Canada. |
Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Colige, A., Rakic, J.-M., Noël, A., Martial, J., & Struman, I. (February 2011). microRNA-21 Exhibits Anti-Angiogenic Function by Targeting RhoB Expression in Endothelial Cells [Poster presentation]. Keystone Symposia : MicroRNAs and Non-Coding RNAs and Cancer, Banff, Alberta, Canada. |
 | COLLIGNON, J., Struman, I., Tabruyn, S., Josse, C., Boukerroucha, M., JERUSALEM, G., & BOURS, V. (2011). Aspects moléculaires du cancer du sein triple négatif et les implications thérapeutiques. Revue Médicale de Liège, 66 (5-6), 393-396. Peer reviewed |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (January 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Giga-Day Symposia, Liège, Belgium. |
Herkenne, S., Bajou, K., D'Amico, S., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2011). Implication of the PAI-1/uPA/uPAR complex in the effects of the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium. |
Bajou, K., Herkenne, S., Thijssen, V. L., D'Amico, S., Srahna, M., Carabin, J.-Y., Gils, A., Declerck, P. J., Griffioen, A. W., Martial, J., & Struman, I. (January 2011). PAI-1 mediates antiangiogenic and fibrinolytic actions of prolactin/growth hormone 16-14K fragments [Poster presentation]. Giga-Day Symposia, Liège, Belgium. |
 | Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., LAMBERT, V., Alvarez Gonzalez, M.-L., Colige, A., Rakic, J.-M., Noël, A., Martial, J., & Struman, I. (2011). MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells. PLoS ONE, 6 (2), 16979. doi:10.1371/journal.pone.0016979 Peer Reviewed verified by ORBi |
 | Kinet, V., Castermans, K., Herkenne, S., Maillard, C., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (2011). The Angiostatic Protein 16K Human Prolactin Significantly Prevents Tumor-Induced Lymphangiogenesis by Affecting Lymphatic Endothelial Cells. Endocrinology. doi:10.1210/en.2011-1081 Peer Reviewed verified by ORBi |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (October 2010). Mir-146a : A new angiostatic miRNA with tumor-suppressive properties [Poster presentation]. Frontiers in Tumor Progression, Madrid, Spain. |
Halkein, J., Tabruyn, S., Malvaux, L., Sabatel, C., Martial, J., & Struman, I. (21 May 2010). miR-146a: an anti-angiogenic miRNA regulated by NF-kB [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Kinet, V., Castermans, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (21 May 2010). 16K human prolactin is an anti-lymphangiogenic factor in vitro and in vivo [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Herkenne, S., Bajou, K., D'Amico, S., Martial, J., & Struman, I. (21 May 2010). Study of the signalling pathway of 16K PRL and 14K GH for mediate their anti-angiogenic effect [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Malvaux, L., Pendeville, H., Sabatel, C., Lambert, V., Nivelles, O., Martial, J., & Struman, I. (21 May 2010). Involvement of miR-125b in in vitro and in vivo angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Martial, J., & Struman, I. (May 2010). Study of the role of miR-21 in the regulation of angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Kinet, V., Castermans, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (March 2010). 16K human prolactin is an anti-lymphangiogenic factor in vitro and in vivo [Poster presentation]. Biomedica, Aachen, Germany. |
Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Martial, J., & Struman, I. (March 2010). Study of the role of miR-21 in the regulation of angiogenesis [Poster presentation]. Biomedica, Aachen, Germany. |
Malvaux, L., Pendeville, H., Sabatel, C., Lambert, V., Nivelles, O., Martial, J., & Struman, I. (March 2010). Involvement of miR-125b in in vitro and in vivo angiogenesis [Poster presentation]. Biomedica, Aachen, Germany. |
 | Sabatel, C., Cornet, A., Tabruyn, S., Malvaux, L., Castermans, K., Martial, J., & Struman, I. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9 (1), 231. doi:10.1186/1476-4598-9-231 Peer Reviewed verified by ORBi |
 | Sliwa, K., Blauwet, L., Tibazarwa, K., Libhaber, E., Smedema, J.-P., Becker, A., McMurray, J., Yamac, H., Labidi, S., Struman, I., & Hilfiker-Kleiner, D. (2010). Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation, 121 (13), 1465-73. doi:10.1161/CIRCULATIONAHA.109.901496 Peer Reviewed verified by ORBi |
Pendeville, H., Nivelles, O., Malvaux, L., Voz, M. L., Martial, J., & Struman, I. (July 2009). Finding miRNAs able to regulate angiogenesis [Poster presentation]. 6ème congrès européen sur le Zebrafish, Amsterdam, Netherlands. |
Pendeville, H., Nivelles, O., Malvaux, L., Voz, M. L., Martial, J., & Struman, I. (29 May 2009). Finding Mir able to regulate angiogenesis [Poster presentation]. GIGA cancer day, Liège, Belgium. |
Malvaux, L., Pendeville, H., Sabatel, C., Martial, J., & Struman, I. (29 May 2009). Study of the role of microRNAs in angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Sabatel, C., Malvaux, L., Cornet, A., Martial, J., & Struman, I. (29 May 2009). Study of the potential regulation of Sprouty1, an angiogenesis inhibitor, by miR-21 [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Nguyen, N.-Q.-N., Camby, S., Lion, M., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the ability of 16K hPRL to affect tumor vessel maturation [Poster presentation]. Biomedica, liège, Belgium. |
Nguyen, N.-Q.-N., Lion, M., Blacher, S., Camby, S., Castermans, K., Noël, A., Martial, J., & Struman, I. (2009). The antiangiogenic factor 16K hPRL affects tumor vessel maturation [Poster presentation]. Giga cancer day, Liège, Belgium. |
Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Bajou, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Big Sky, United States - Montana. |
Castermans, K., Nguyen, N.-Q.-N., Lecomte, J., Noël, A., Martial, J., & Struman, I. (2009). The contribution of vasculogenesis to tumor neovascularization after angiostatic treatment [Poster presentation]. Giga cancer day, liège, Belgium. |
Halkein, J., Malvaux, L., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2009). Involvement of microRNAs in the regulation of angiogenesis by the antiangiogenic factor 16K [Poster presentation]. Biomedica, Liège, Belgium. |
 | Tabruyn, S., Memet, S., Ave, P., Verhaeghe, C., Mayo, K. H., Struman, I., Martial, J., & Griffioen, A. W. (2009). NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Molecular Cancer Therapeutics, 8 (9), 2645-54. doi:10.1158/1535-7163.MCT-09-0383 Peer Reviewed verified by ORBi |
Halkein, J., Malvaux, L., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2009). Regulation of microRNAs expression by the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium. |
Nguyen, N.-Q.-N., Camby, S., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Study of the effect of the antiangiogenic factor 16K hPRL in tumor vessel maturation [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Bozeman, United States - Montana. |
Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Letters, 284 (2), 222-228. doi:10.1016/j.canlet.2009.04.030 Peer Reviewed verified by ORBi |
Weiner, R. I., Martial, J., Struman, I., Taylor, R., & Bentzien, F. (17 April 2008). Novel antiangiogenic peptide agents and their therapeutic and diagnostic use. |
Sabatel, C., Tabruyn, S., Cornet, A., Martial, J., & Struman, I. (30 March 2008). Study of the role of Sprouty1 in the regulation of angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Martial, J., Struman, I., Nguyen, N.-Q.-N., Brasseur, R., & Lins, L. (14 February 2008). Antiangiogenic peptides. |
Pendeville-Samain, H., Winandy, M., Manfroid, I., Nivelles, O., Motte, P., Pasque, V., Peers, B., Struman, I., Martial, J., & Voz, M. (2008). Zebrafish Sox7 and Sox18 function together to control arterial-venous identity. Developmental Biology, 317 (2), 405-16. doi:10.1016/j.ydbio.2008.01.028 Peer Reviewed verified by ORBi |
 | Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (December 2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Molecular Therapy, 15 (12), 2094-2100. doi:10.1038/sj.mt.6300294 Peer Reviewed verified by ORBi |
 | Erdmann, S., Ricken, A., Merkwitz, C., Struman, I., Castino, R., Hummitzsch, K., Gaunitz, F., Isidoro, C., Martial, J., & Spanel-Borowski, K. (November 2007). The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. American Journal of Physiology - Endocrinology and Metabolism, 293 (5), 1365-E1377. doi:10.1152/ajpendo.00280.2007 Peer Reviewed verified by ORBi |
 | Huynh-Thu, V. A., Hiard, S., Geurts, P., Muller, M., Struman, I., Martial, J., & Wehenkel, L. (September 2007). Detection of micro-RNA/gene interactions involved in angiogenesis using machine learning techniques [Poster presentation]. Workshop on Machine Learning in Systems Biology (MLSB07), Evry, France. Peer reviewed |
Martial, J., Struman, I., Nguyen, N.-Q.-N., Brasseur, R., & Lins, L. (02 May 2007). Antiangiogenic peptides. |
Hilfiker-Kleiner, D., Kaminski, K., Podewski, E., Bonda, T., Schaefer, A., Sliwa, K., Forster, O., Quint, A., Landmesser, U., Doerries, C., Luchtefeld, M., Poli, V., Schneider, M. D., Balligand, J. L., Desjardins, F., Ansari, A., Struman, I., Nguyen, N.-Q.-N., Zschemisch, N. H., ... Drexler, H. (09 February 2007). A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 128 (3), 589-600. doi:10.1016/j.cell.2006.12.036 Peer Reviewed verified by ORBi |
Kinet, V., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (2007). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia:Host cell response to cancer, Keystone, United States - Colorado. |
Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Gordon research on angiogenesis, Newport, United States - Rhode Island. |
Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., FOIDART, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Keystone symposia: Host cell response to cancer, Bozeman, United States - Montana. |
Sabatel, C., Tabruyn, S., Cornet, A., Griffioen, A., Martial, J., & Struman, I. (January 2007). Study of the molecular mechanisms involved in the response of tumor and host to the treatment with the antiangiogenic factor 16K prolactin [Poster presentation]. Host cell response to cancer, Keystone, United States. |
Hilfiker-Kleiner, D., Meyer, G. P., Schieffer, E., Goldmann, B., Podewski, E., Struman, I., Fischer, P., & Drexler, H. (2007). Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. Journal of the American College of Cardiology, 50 (24), 2354-5. doi:10.1016/j.jacc.2007.10.006 Peer Reviewed verified by ORBi |
Tabruyn, S., Sabatel, C., Nguyen, N.-Q.-N., Verhaeghe, Castermans, K., Malvaux, L., Griffioen, A. W., Martial, J., & Struman, I. (2007). The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Molecular Endocrinology, 21 (6), 1422-9. doi:10.1210/me.2007-0021 Peer Reviewed verified by ORBi |
Cornet, A., Nguyen, N.-Q.-N., Lion, M., Tabruyn, S., Sabatel, C., Kinet, V., Noël, A., Beckers, M.-C., Struman, I., & Martial, J. (May 2006). Molecular profiling of 16K PRL treated tumours by an antibody-array approach [Poster presentation]. Bioforum, Liège, Belgium. |
 | Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Lair, F., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103 (39), 14319-14324. doi:10.1073/pnas.0606638103 Peer Reviewed verified by ORBi |
Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Tilted peptides of PRL/GH family and their potential role in angiogenesis [Poster presentation]. Bioforum, Liège, Belgium. |
Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Adenovirus-mediated gene transfer of 16K prolactin inhibits B16-F10 tumor growth and metastasis [Poster presentation]. Bioforum, Liège, Belgium. |
Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Evaluation of 16K Prolactin to prevent metastatic spread through inhibition of angiogenesis [Poster presentation]. Gordon Research Conference: Prolactin Family, Ventura, United States - California. |
Tabruyn, S., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (July 2005). The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G(0)-G(1) and the G(2)-M phases. Molecular Endocrinology, 19 (7), 1932-1942. doi:10.1210/me.2004-0515 Peer Reviewed verified by ORBi |
Ricken, A., Merkwitz, C., Struman, I., Martial, J., & Spanel-Borowski, K. (2005). Evidence for a role of prolactin fragments in corpus luteum function. In The society for the study of reproduction Annual meeeting, Quebec 2005 (pp. 240-241). Madison, United States - Wisconsin: Soc Study Reproduction. Peer reviewed |
 | Piwnica, D., Touraine, P., Struman, I., Tabruyn, S., Bolbach, G., Clapp, C., Martial, J., Kelly, P. A., & Goffin, V. (October 2004). Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance. Molecular Endocrinology, 18 (10), 2522-2542. doi:10.1210/me.2004-0200 Peer Reviewed verified by ORBi |
 | Pan, H., Nguyen, N.-Q.-N., Yoshida, H., Bentzien, F., Shaw, L. C., Rentier-Delrue, F., Martial, J., Weiner, R., Struman, I., & Grant, M. B. (July 2004). Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Investigative Ophthalmology and Visual Science, 45 (7), 2413-2419. doi:10.1167/iovs.03-1001 Peer Reviewed verified by ORBi |
Tabruyn, S., Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (14 May 2004). Molecular mechanisms involved in apoptosis and cell cycle arrest induced by the antiangiogenic factor 16K hPRL [Poster presentation]. Faseb meeting 2005. |
Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (2004). The 16 kDa N-terminal fragment of the human prolactin. Design and production of minimal peptides retaining antiangiogenic and antitumoral properties [Poster presentation]. Association belge pour l’étude du cancer, Liège, Belgium. |
Tabruyn, S., Sorlet, C. M., Rentier-Delrue, F., Bours, V., Weiner, R. I., Martial, J., & Struman, I. (September 2003). The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappa B. Molecular Endocrinology, 17 (9), 1815-1823. doi:10.1210/me.2003-0132 Peer Reviewed verified by ORBi |
Tabruyn, S., Sorlet, C., Georges, A., Rentier-Delrue, F., Martial, J., & Struman, I. (2003). 16K hPRL prevents angiogenesis by inducing both apoptosis and cell cycle arrest of endothelial cells [Poster presentation]. Euroconférences: Angiogenesis 2, Paris, France. |
Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (2003). Design and production of minimal peptides that retain antiangiogenic and antitumoral properties of the 16K N-terminal fragment of the human prolactin [Poster presentation]. Euroconférences: Angiogenesis 2, Paris, France. |
 | Bentzien, F., Struman, I., Martini, J. F., Martial, J., & Weiner, R. (2001). Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Research, 61 (19), 7356-62. Peer Reviewed verified by ORBi |
Struman, I., Sorlet, Vilour, J., Bentzien, F., Lee, H., Rentier-Delrue, F., Lion, M., Weiner, R. I., & Martial, J. (February 2000). The 16 kDa fragments of the PRL/GH family inhibit angiogenesis whereas the full-length hormones stimulate blood vessel formation [Poster presentation]. Gordon Conference on Prolactin, Ventura, California, United States. |
 | Martini, J. F., Piot, C., Humeau, L. M., Struman, I., Martial, J., & Weiner, R. I. (2000). The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Molecular Endocrinology, 14 (10), 1536-49. doi:10.1210/mend.14.10.0543 Peer Reviewed verified by ORBi |
Corbacho, A. M., Nava, G., Eiserich, J. P., Noris, G., Macotela, Y., Struman, I., Martinez De La Escalera, G., Freeman, B. A., & Clapp, C. (2000). Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin. Journal of Biological Chemistry, 275 (18), 13183-6. doi:10.1074/jbc.275.18.13183 Peer Reviewed verified by ORBi |
 | Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D'Angelo, G., Goffin, V., Weiner, R. I., & Martial, J. (10 February 1999). Opposing Actions of Intact and N-Terminal Fragments of the Human Prolactin/Growth Hormone Family Members on Angiogenesis: An Efficient Mechanism for the Regulation of Angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 96 (4), 1246-51. doi:10.1073/pnas.96.4.1246 Peer Reviewed verified by ORBi |
Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D'Angelo, G., Goffin, V., Weiner, R. I., & Martial, J. (January 1998). Antagonistic regulation by intact and N-terminal fragment of the human Prolactin/Growth Hormone family members : a novel mechanism for regulation of angiogenesis [Poster presentation]. American association for cancer research, Angiogenesis and Cancer, Orlando, United States. |
Mainfroid, V., Struman, I., Weiner, R. I., & Martial, J. (January 1998). Design and characterization of novel forms of human 16K prolactin, an antiangiogenic factor [Poster presentation]. American association for cancer research, Angiogenesis and Cancer, Orlando, United States. |
 | Lee, H., Struman, I., Clapp, C., Martial, J., & Weiner, R. I. (1998). Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology, 139 (9), 3696-703. doi:10.1210/endo.139.9.6194 Peer Reviewed verified by ORBi |
Struman, I., Mainfroid, V., Bentzien, F., Weiner, R. I., Goffin, V., & Martial, J. (September 1997). Opposite actions of human Prolactin and its 16-kDa fragment on Angiogenesis [Poster presentation]. Philippe Laudat Conferences - Biology and Physiopathology of Angiogenesis, Aix les Bains, France. |
 | D'Angelo, G., Struman, I., Martial, J., & Weiner, R. I. (1995). Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proceedings of the National Academy of Sciences of the United States of America, 92 (14), 6374-8. doi:10.1073/pnas.92.14.6374 Peer Reviewed verified by ORBi |
 | Goffin, V., Struman, I., Mainfroid, V., Kinet, S., & Martial, J. (23 December 1994). Evidence for a Second Receptor Binding Site on Human Prolactin. Journal of Biological Chemistry, 269 (51), 32598-606. Peer Reviewed verified by ORBi |
 | Goffin, V., Struman, I., Goormaghtigh, E., & Martial, J. (01 June 1993). The Addition of Nine Residues at the C-Terminus of Human Prolactin Drastically Alters Its Biological Properties. European Journal of Biochemistry, 214 (2), 483-90. doi:10.1111/j.1432-1033.1993.tb17945.x Peer Reviewed verified by ORBi |
De Moerlooze, L., Struman, I., Renard, A., & Martial, J. (21 September 1992). Stabilization of T7-Promoter-Based Parhs Expression Vectors Using the Parb Locus. Gene, 119 (1), 91-3. doi:10.1016/0378-1119(92)90070-6 Peer Reviewed verified by ORBi |
